Market Research Logo

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary

According to the recently published report 'NT 3 Growth Factor Receptor - Pipeline Review, H2 2018'; NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules.

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation.

The report 'NT 3 Growth Factor Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Genetic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Neuroblastoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Biliary Tumor, Brain Tumor, Cancer Pain, Cervical Cancer, Charcot-Marie-Tooth Disease, Gastrointestinal Stromal Tumor (GIST), Glioma, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Synovial Sarcoma and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
  • The report reviews NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Handok Inc
Ignyta Inc
Loxo Oncology Inc
Plexxikon Inc
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles
AZD-7451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
May 29, 2018: U.S. FDA accepts larotrectinib New Drug Application and grants priority review
May 17, 2018: Bayer Provides Update on larotrectinib at ASCO
Mar 26, 2018: Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Feb 21, 2018: Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers
Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH
Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients with ROS1-Positive Non-Small Cell Lung Cancer
Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer
Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer
Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Handok Inc, H2 2018
Pipeline by Ignyta Inc, H2 2018
Pipeline by Loxo Oncology Inc, H2 2018
Pipeline by Plexxikon Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report